NasdaqGS:ASNDBiotechs
Ascendis Pharma (ASND): Revisiting Valuation After Recent Pullback and Strong 1-Year Shareholder Returns
Ascendis Pharma (ASND) has quietly given back some ground over the past week, even though its longer term performance remains strong. With shares near 200 dollars, investors are weighing solid growth against ongoing losses.
See our latest analysis for Ascendis Pharma.
Despite the recent 7 day share price return of negative 9.4 percent, Ascendis still boasts a robust year to date share price return of about 45 percent and a 1 year total shareholder return of roughly 47 percent. This suggests...